| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Giuseppe Battaglia, Carla L Busceti, Gemma Molinaro, Francesca Biagioni, Anna Traficante, Ferdinando Nicoletti, Valeria Brun. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 27. 2006-07-25. PMID:16822979. |
phccc treatment (3 or 10 mg/kg) significantly reduced mptp toxicity, as assessed by measurements of the striatal levels of dopamine and its metabolites and by tyrosine hydroxylase, dopamine transporter, and glial fibrillary acidic protein immunostaining in the corpus striatum and substantia nigra. |
2006-07-25 |
2023-08-12 |
mouse |
| Jackalina M Van Kampen, Christopher B Eckma. Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 27. 2006-07-25. PMID:16822985. |
pharmacological activation of the dopamine d3 receptor has been shown to trigger neurogenesis in the substantia nigra of the adult rat brain. |
2006-07-25 |
2023-08-12 |
rat |
| Sara González, Camila Scorticati, Moisés García-Arencibia, Rosario de Miguel, José A Ramos, Javier Fernández-Rui. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain research. vol 1073-1074. 2006-07-19. PMID:16412990. |
dose-response studies with 6-hydroxydopamine revealed that the application of 200 microg per animal caused hypokinetic signs (decreased ambulatory activity, increased inactivity, and reduced motor coordination), which paralleled several signs of degeneration of nigrostriatal dopaminergic neurons (dopamine depletion in the caudate-putamen, and decreased mrna levels for tyrosine hydroxylase and superoxide dismutase-1 and -2 in the substantia nigra). |
2006-07-19 |
2023-08-12 |
rat |
| Philippe Vernier, Frederic Moret, Sophie Callier, Marina Snapyan, Christophe Wersinger, Anita Sidh. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system. Annals of the New York Academy of Sciences. vol 1035. 2006-07-13. PMID:15681811. |
in this respect, mesencephalic dopamine neurons of the substantia nigra and ventral tegmental area are characterized by a molecular combination (tyrosine hydroxylase, aromatic amino acid decarboxylase, monoamine oxidase, vesicular monoamine transporter, dopamine transporter--to name a few), which is not found in other dopamine-containing neurons of the vertebrate brain. |
2006-07-13 |
2023-08-12 |
human |
| F P Manfredsson, A S Lewin, R J Mande. RNA knockdown as a potential therapeutic strategy in Parkinson's disease. Gene therapy. vol 13. issue 6. 2006-06-29. PMID:16267570. |
rna interference can theoretically be applied to parkinson's disease since over-expression of various proteins is known to kill the dopamine neurons of the substantia nigra in animal models and in familial forms of parkinson's disease. |
2006-06-29 |
2023-08-12 |
Not clear |
| M E Olds, D B Jacques, O Kopyo. Relation between rotation in the 6-OHDA lesioned rat and dopamine loss in striatal and substantia nigra subregions. Synapse (New York, N.Y.). vol 59. issue 8. 2006-06-16. PMID:16565974. |
relation between rotation in the 6-ohda lesioned rat and dopamine loss in striatal and substantia nigra subregions. |
2006-06-16 |
2023-08-12 |
rat |
| M E Olds, D B Jacques, O Kopyo. Relation between rotation in the 6-OHDA lesioned rat and dopamine loss in striatal and substantia nigra subregions. Synapse (New York, N.Y.). vol 59. issue 8. 2006-06-16. PMID:16565974. |
the relation between the rotation response to drug-induced activation of the dopamine (da) receptor in the rat unilaterally lesioned with 6-hydroxydopamine (6-ohda) in the substantia nigra (sn) and the loss of da in subregions of the sn and caudate-putamen (c/put) is not clear. |
2006-06-16 |
2023-08-12 |
rat |
| A Lieberma. Depression in Parkinson's disease -- a review. Acta neurologica Scandinavica. vol 113. issue 1. 2006-06-08. PMID:16367891. |
these observations and reports of depression during deep brain stimulation of regions contiguous to the substantia nigra, as well as reports of dopamine agonist improving depression, suggest depression, rather than being mainly a psychological reaction to a debilitating disease, is part of pd. |
2006-06-08 |
2023-08-12 |
Not clear |
| Anya M Y Lin, K B Chen, P L Cha. Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Annals of the New York Academy of Sciences. vol 1053. 2006-06-06. PMID:16179538. |
intranigral infusion of zinc elevated lipid peroxidation in the infused substantia nigra and depleted striatal dopamine content at 7 days after infusion. |
2006-06-06 |
2023-08-12 |
Not clear |
| H Yamaguchi, K Kajitani, Y Dan, M Furuichi, M Ohno, K Sakumi, D Kang, Y Nakabepp. MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Cell death and differentiation. vol 13. issue 4. 2006-06-05. PMID:16273081. |
we previously reported that 8-oxoguanine (8-oxog) accumulates in the cytoplasm of dopamine neurons in the substantia nigra of patients with parkinson's disease and the expression of mth1 carrying an oxidized purine nucleoside triphosphatase activity increases in these neurons, thus suggesting that oxidative damage in nucleic acids is involved in dopamine neuron loss. |
2006-06-05 |
2023-08-12 |
mouse |
| Danqing Xiao, Gregory M Miller, Amy Jassen, Susan V Westmoreland, Douglas Pauley, Bertha K Madra. Ephrin/Eph receptor expression in brain of adult nonhuman primates: implications for neuroadaptation. Brain research. vol 1067. issue 1. 2006-05-02. PMID:16360648. |
evidence for epha4 expression in dopamine neurons emerged from colocalization with tyrosine-hydroxylase-positive terminals in striatum and substantia nigra and ventral tegmental area cell bodies. |
2006-05-02 |
2023-08-12 |
monkey |
| George K Tofaris, Pablo Garcia Reitböck, Trevor Humby, Sarah L Lambourne, Mark O'Connell, Bernardino Ghetti, Helen Gossage, Piers C Emson, Lawrence S Wilkinson, Michel Goedert, Maria Grazia Spillantin. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 15. 2006-05-02. PMID:16611810. |
here, we show that the expression of truncated human alpha-synuclein(1-120), driven by the rat tyrosine hydroxylase promoter on a mouse alpha-synuclein null background, leads to the formation of pathological inclusions in the substantia nigra and olfactory bulb and to a reduction in striatal dopamine levels. |
2006-05-02 |
2023-08-12 |
mouse |
| Peter Klivenyi, Donald Siwek, Gabrielle Gardian, Lichuan Yang, Anatoly Starkov, Carine Cleren, Robert J Ferrante, Neil W Kowall, Asa Abeliovich, M Flint Bea. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of disease. vol 21. issue 3. 2006-04-28. PMID:16298531. |
there was dose-dependent protection against loss of both dopamine in the striatum and dopamine transporter (dat) immunoreactive neurons in the substantia nigra. |
2006-04-28 |
2023-08-12 |
mouse |
| F Fumagalli, G Racagni, M A Riv. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. The pharmacogenomics journal. vol 6. issue 2. 2006-04-28. PMID:16402079. |
brain-derived neurotrophic factor (bdnf) colocalizes with dopamine neurons in the substantia nigra, where dopaminergic cell bodies are located, and it has recently garnered attention as a molecule crucial for cognition, a function that is also compromised in pd patients. |
2006-04-28 |
2023-08-12 |
Not clear |
| Claire Henchcliffe, H Christian Schumacher, F Tuna Burgu. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert review of neurotherapeutics. vol 5. issue 6. 2006-04-18. PMID:16274338. |
monoamine oxidase inhibitors inhibit dopamine metabolism and are therefore effective in treating parkinson's disease, a condition associated with progressive striatal dopamine deficiency secondary to degeneration of dopaminergic neurons in the substantia nigra. |
2006-04-18 |
2023-08-12 |
Not clear |
| Janice M Phillips, Hoa A Lam, Larry C Ackerson, Nigel T Maidmen. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. The European journal of neuroscience. vol 23. issue 1. 2006-04-06. PMID:16420425. |
a battery of simple behavioral tests, reliably sensitive to dopamine depletion, was applied consecutively: (i) prior to surgery; (ii) 3 weeks following a unilateral 6-hydroxydopamine lesion of the substantia nigra pars compacta; (iii) at 1 h, 24 h and 4 days following a microinjection of mpep, via an indwelling cannula, into the stn, entopeduncular nucleus (ep) or substantia nigra zona reticulata. |
2006-04-06 |
2023-08-12 |
rat |
| Naira Pereyra-Muñoz, Concepción Rugerio-Vargas, Mariana Angoa-Pérez, Gabino Borgonio-Pérez, Selva Rivas-Arancibi. Oxidative damage in substantia nigra and striatum of rats chronically exposed to ozone. Journal of chemical neuroanatomy. vol 31. issue 2. 2006-04-04. PMID:16236481. |
each group was then tested for (1) motor activity, (2) quantification of lipid peroxidation levels, (3) klüver-barrera staining, and (4) immunohistochemistry for tyrosine hydroxylase (th), dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein of 32 kd (darpp-32), inducible nitric oxide synthase (inos), and superoxide dismutase (sod), to study neuronal alterations in striatum and substantia nigra. |
2006-04-04 |
2023-08-12 |
rat |
| Renee M Miller, Gretchen L Kiser, T M Kaysser-Kranich, Randall J Lockner, Chockalingam Palaniappan, Howard J Federof. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiology of disease. vol 21. issue 2. 2006-03-29. PMID:16143538. |
we hypothesize that specific differential gene expression underlies important pathogenic processes in parkinson's disease, which is characterized by the gradual loss of dopaminergic neurons in the substantia nigra and consequent loss of dopamine in the striatum. |
2006-03-29 |
2023-08-12 |
human |
| Erica L Unger, David J Eve, Xiomara A Perez, Dawn K Reichenbach, Yanqun Xu, Michael K Lee, Anne M Andrew. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiology of disease. vol 21. issue 2. 2006-03-29. PMID:16230020. |
hyperactivity in a53t-tg mice was also associated with increased d1 receptor expression in the substantia nigra and decreased dopamine transporter expression in the nucleus accumbens and striatum. |
2006-03-29 |
2023-08-12 |
mouse |
| J M Van Kampen, H A Robertso. A possible role for dopamine D3 receptor stimulation in the induction of neurogenesis in the adult rat substantia nigra. Neuroscience. vol 136. issue 2. 2006-03-17. PMID:16216425. |
a possible role for dopamine d3 receptor stimulation in the induction of neurogenesis in the adult rat substantia nigra. |
2006-03-17 |
2023-08-12 |
rat |